PRICING AND MARKET ACCESS

Optimize patient value and access

IQVIA Value and Access (V&A) Strategy Consulting helps you define and defend product value across the entire lifecycle. Our customized solutions and proprietary tools support enhanced access to your treatments.

Solutions Commercialization Pricing and Market Access

PriceBOX

2250+ PROJECTS COMPLETED

425+ DRUG PRODUCTS

325+ THERAPEUTIC AREAS

250+ PRICING and MARKET ACCESS EXPERTS IN NETWORK

100+ COUNTRIES

IQVIA’s V&A Team can provide end-to-end support across the globe

PEOPLE

We help you discover unrealized connections and see solutions through the lens of insight, yielding and implementing breakthrough ideas

EXPERTISE

Our deep, global expertise spans clinical to commercial functions in multiple therapeutic areas and is powered by our highly-trained market access experts with global and local expertise

CONNECTED CAPABILITIES

Through proprietary data, technology, and advanced analytics and methodologies, we help you bring innovative therapies to patients

Market Access

Value and Access Strategy Consulting

Support clients with a key strategic goal that underpins successful launches:

Leverage evidence to drive patient access at a price that maximizes value for healthcare Stakeholders.

HTA Accelerator

The Health Technology Assessment Accelerator (HTAA) from IQVIA allows the user to analyze past and current payer assessments and evidence requirements to guide clinical trial design and market access strategy across the product lifecycle.

IQVIA HTAA is now bigger and better after our recent acquisition of Prism access and can offer best-in-class tools to boost your V&A strategy through its dashboards, allowing for quick display of regulatory, clinical, HTA, and pricing approaches/decisions

Learn more

Market Access Planning (MAP) Tool

The Market Access Planning Platform (MAP) is a web-based, comprehensive solution to navigate the market access roadmap. It allows the user to create and monitor personalized market access plans for an entire global portfolio, while improving organizational communication and efficacy.

IRP Tool

Over time, International Reference Pricing (IRP) can have a serious impact on your business. IQVIA’s IRP tool not only assesses the impact of IRP rules by country, but it also allows you to run “what if” scenarios to understand the impact of different variables (referencing events, list/net price changes, volume adjustments, country of origin, etc.) on your optimal launch sequence, margins, and other key business decisions and metrics.

E-Groups

The IQVIA e-Group is a convenient, interactive, online research platform with the ability to gather qualitative feedback, post follow-up questions, and conduct exercises (e.g., polling, rating) across respondents.

The tool also allows flexible recruitment of respondents specifically identified to best answer the research questions, without availability, language (multi-language function), or time zone concerns.

Explore the impact of the IRA and outlook for the industry

The Inflation Reduction Act (IRA) continues to disrupt the life sciences industry and muddy future expectations for many brands. The IQVIA U.S. Market Access Center of Excellence is at the forefront of interpreting the implications of this landmark legislation and providing insights that may be beneficial for your brand. Discover the insights to help position your products for success.

LEARN MORE

IQVIA recognized as Leader by industry analysts Everest Group

The 2023 Everest Group Life Sciences Operations PEAK Matrix® Assessment evaluated products from 28 companies serving the industry.

IQVIA was named a “Leader” and positioned highest of all companies surveyed.

Please click below to access the custom report for more details.

ACCESS REPORT

IQVIA named highest positioned Leader by Everest Group

The 2023 Everest Group’s Life Sciences Sales and Marketing Operations PEAK Matrix^® Assessment evaluated 17 life sciences sales and marketing operations providers serving the industry.

IQVIA was the highest-scoring provider named in the Leader category.

ACCESS REPORT

Explore More

PriceBOX

PRICING AND MARKET ACCESS

Optimize patient value and access

2250+ PROJECTS COMPLETED

425+ DRUG PRODUCTS

325+ THERAPEUTIC AREAS

250+ PRICING and MARKET ACCESS EXPERTS IN NETWORK

100+ COUNTRIES

IQVIA’s V&A Team can provide end-to-end support across the globe

Market Access

Value and Access Strategy Consulting

HTA Accelerator

Market Access Planning (MAP) Tool

IRP Tool

E-Groups

Explore the impact of the IRA and outlook for the industry

IQVIA recognized as Leader by industry analysts Everest Group

IQVIA named highest positioned Leader by Everest Group

How Emerging Biopharma Companies Can Prepare for EU HTA

HTA Changes in the U.S. and EU

Cell and Gene Therapy: How Can They Be the Future of Healthcare with So Many Market Access Challenges?

Now Trending: Biosimilars

Making the Right Moves Part 1: Preparing for Part D Liabilities from the Inflation Reduction Act

Making The Right Moves Part 2: Price Pressures from the Inflation Reduction Act

Expanding Considerations in Oncology Access

Journey into the Whirlwind

Not All Fixed Dose Combinations (FDCs) are Equal

Journey Into the Whirlwind: Post-COVID pricing and evidence policy changes and their implications for development and commercialization

US Market Access Quarterly Advisor 4th Quarter 2022

Impact of RWE on HTA Decision-making

Explore More

PRICING AND MARKET ACCESS

Optimize patient value and access

2250+ PROJECTS COMPLETED

425+ DRUG PRODUCTS

325+ THERAPEUTIC AREAS

250+ PRICING and MARKET ACCESS EXPERTS IN NETWORK

100+ COUNTRIES

IQVIA’s V&A Team can provide end-to-end support across the globe

Market Access

Value and Access Strategy Consulting

HTA Accelerator

Market Access Planning (MAP) Tool

IRP Tool

E-Groups

Explore the impact of the IRA and outlook for the industry

IQVIA recognized as Leader by industry analysts Everest Group

IQVIA named highest positioned Leader by Everest Group

Our latest thinking on navigating market access

Explore More